Trial Profile
Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2023 Primary endpoint has been met, (Progression Free Survival (PFS), as per Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Final Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 11 Nov 2022 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.